At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses ARAMIS, a multinational, randomised, double-blind, placebo-controlled, phase 3 trial that is evaluating the efficacy and safety study of ODM-201, a novel second-generation oral androgen receptor inhibitor, in men with high-risk non-metastatic castration-resistant prostate cancer.
ARAMIS trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer
26th August 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now